Nova Eye Medical (ASX:EYE): iTrack(TM) Advance Approved for Sale in China
Nova Eye Medical (ASX:EYE)
-
The National Medical Products Administration (NMPA) has approved the registration of the iTrack™ Advance in China
-
Nova Eye has an established, experienced channel partner in China who will expedite market access and manage sales
-
Sales growth expected from late FY26
Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), today announced that the National Medical Products Administration (NMPA), has registered iTrack™ Advance in China.
The successful registration of the iTrack™ Advance in China is a pivotal milestone in the Company’s strategy to expand global sales of its iTrack™ portfolio for the surgical treatment of glaucoma.
Expansion of Surgeon User Base in China is Expected
The original iTrack™ device has been well accepted by Chinese surgeons. The latest generation iTrack™ Advance offers significant improvements in surgical efficiency and is expected to appeal to a broad cross section of Chinese surgeons. This is expected to drive significant sales growth in the long term.
The Company’s revenues generated from sales of the original iTrack™ device in China were US$1.2 million for the year ended 30 June 2025. Pre-launch initiatives with our exclusive channel partner in China will commence immediately. Sales growth is expected from late FY26 and beyond.
Nova Eye Medical Managing Director, Tom Spurling, commented: “We are delighted to secure NMPA approval for iTrack™ Advance, building on our track record in China with the original iTrack™ device.
Our established local sales partner is well positioned to direct our program of market access, sales and marketing activities for the iTrack™ Advance.
Importantly, this milestone comes at a time when Chinese surgeons are being influenced by the paradigm shift toward interventional glaucoma, which is currently driving growth of our treatment technologies in the USA.”
Market Opportunity in China compared with USA
A comparison of the glaucoma market opportunity in the USA compared with China in described in Table 1.
Table 1: Comparative glaucoma market opportunity in the USA and China
(Source: Marketscope 2025 Glaucoma Surgical Devices Report and Company records).
Read the ASX Announcement here: iTrack™ Advance Approved for Sale in China
Learn more about iTrack™ Advance: iTrack™ Advance: Advancing canaloplasty to the next level.
Visit our company website: Nova Eye Medical Limited
About us:
Nova Eye Medical Limited (ASX:EYE) is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.
Contact details:
Company
Tom Spurling
Managing Director
+61 417 818 658
Investors
Mark Flynn
Investor Relations
+61 416 068 733
- Images
-
Download
iTrack Advance-angled-Nova Eye Medical.jpg
Nova Eye Medical's flagship product - the iTrack(TM) Advance - is a FDA-approved, stent-free, tissue-preserving glaucoma solution. -
Download
DSC04301.JPG
iTrack(TM)Advance: Canaloplasty-based procedure; Enhances natural drainage - "angioplasty of the eye"; No stent, no implant, no foreign material left behind; FDA approved April 2023; 165,000 procedures globally -
Download
UV4K-0303.jpg
Nova Eye U.S. iTrack(TM) Advance procedures (2025): approx.14,000. These sales are being made primarily to glaucoma surgeons and progressively we are accessing cataract surgeons and generalists.
